1. Home
  2. GXAI vs BIVI Comparison

GXAI vs BIVI Comparison

Compare GXAI & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gaxos.ai Inc.

GXAI

Gaxos.ai Inc.

HOLD

Current Price

$1.38

Market Cap

13.5M

Sector

N/A

ML Signal

HOLD

Logo BioVie Inc.

BIVI

BioVie Inc.

HOLD

Current Price

$1.64

Market Cap

11.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GXAI
BIVI
Founded
2021
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.5M
11.5M
IPO Year
2022
2013

Fundamental Metrics

Financial Performance
Metric
GXAI
BIVI
Price
$1.38
$1.64
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
3.1M
106.8K
Earning Date
05-14-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
71.35
N/A
EPS
N/A
N/A
Revenue
$1,933,030.00
N/A
Revenue This Year
$271.23
N/A
Revenue Next Year
$36.32
N/A
P/E Ratio
N/A
N/A
Revenue Growth
47901.74
N/A
52 Week Low
$1.02
$0.88
52 Week High
$2.96
$9.09

Technical Indicators

Market Signals
Indicator
GXAI
BIVI
Relative Strength Index (RSI) 64.58 57.50
Support Level $1.06 $1.17
Resistance Level $1.69 $1.71
Average True Range (ATR) 0.13 0.14
MACD 0.03 0.03
Stochastic Oscillator 29.36 68.75

Price Performance

Historical Comparison
GXAI
BIVI

About GXAI Gaxos.ai Inc.

Gaxos.AI Inc is a technology company focused on reshaping the way people interact with artificial intelligence across everyday life and high-impact industries. It is engaged in building a portfolio of AI-powered solutions designed to make advanced technology more practical, accessible, and transformative. The company's portfolio spans defense, health and wellness, entertainment, and productivity - bringing intelligent tools to markets where innovation can drive meaningful real-world outcomes. It operates as a single operating segment technology-based company that is developing applications aimed at redefining the way it utilizes artificial intelligence (AI) to optimize the user experience.

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Share on Social Networks: